How Interest Rates Control Biotech Stocks

Most biotech investors obsess over the wrong thing. They track PDUFA dates, clinical trial readouts, and FDA advisory committee votes. Those matter. But the single biggest driver of whether your biotech portfolio is up or down this year has nothing to do with any drug. It’s the 10-year Treasury yield.

Here’s why that number controls biotech stocks more than any Phase 3 readout.

The Problem

You buy a biotech stock with strong Phase 2 data, a clear catalyst path, and 18 months of cash runway. Six months later it’s down 40%. The trial hasn’t failed. The pipeline hasn’t changed. What happened? The Federal Reserve raised interest rates, and that math matters more than any single data point.

The Mechanism: Why Biotech Is the Most Rate-Sensitive Sector

A biotech company’s value is almost entirely future cash flows, discounted back to today. A pre-revenue biotech with a drug in Phase 3 won’t generate meaningful revenue until year 3 or 4 at the earliest. A platform biotech’s value can sit 10 years out.

Here’s the formula, in plain English:

Present Value = Future Cash Flows ÷ (1 + discount rate)^years

If your drug is projected to earn $500 million per year starting in 2034, 8 years from now, and the discount rate (which includes the risk-free rate from Treasuries) is 3%, that $500 million is worth about $395 million today. At a 5% discount rate, it’s worth $338 million. At a 7% rate, it drops to $291 million.

That’s a 26% haircut on a single year’s distant cash flow, just from rates moving. Multiply that across a decade of projected revenue and the present value of the company can drop 40-60% without any news about the drug itself.

Biotech is uniquely vulnerable to this math because there are no current earnings to anchor the valuation. A utility company trades on its dividend. A mega-cap pharma like Johnson & Johnson has $90 billion in annual revenue providing a floor. A Phase 2 biotech has zero revenue and a thesis that lives entirely in the future. When the discount rate rises, that future shrinks.

The 2022 Case Study: XBI’s 64% Crash

In February 2021, the SPDR S&P Biotech ETF (XBI) hit an all-time high of roughly $174. By May 2022, it traded near $62. That’s a 63.89% peak-to-trough drawdown, the worst in XBI’s history.

What caused it? The Federal Reserve launched the fastest rate-hiking cycle in 40 years. The federal funds rate went from near-zero (0-0.25%) in March 2022 to 5.25-5.50% by July 2023. The 10-year Treasury yield, which is the benchmark for discounting future cash flows, surged from roughly 1.5% to over 4%.

The S&P 500 fell about 19% in 2022. XBI fell over three times that. Same macro event, dramatically different impact because biotech’s value sits almost entirely in the future.

And it wasn’t just stock prices. As rates rose and risk appetite collapsed, the biotech IPO market froze. Only 8 biotech companies went public in all of 2025, a decade low. Companies that were burning $40 million per quarter could no longer raise money. Cash runways evaporated. Dilution hit at fire-sale prices. The rate cycle didn’t just reprice biotech equities; it cut off the oxygen supply.

The 2024-2026 Pivot: What Falling Rate Expectations Did

When the Fed signaled the hiking cycle was ending and markets began pricing in rate cuts, biotech snapped back. The XBI returned +72.46% in the year through July 2026 and is up another 20%+ year-to-date.

The IPO window reopened. Biotech IPOs surged from 8 in all of 2025 to 18 in the first half of 2026 alone. As of August, 20 deals have priced for roughly $6.4 billion in total proceeds, making 2026 the busiest year for biotech IPOs since the 2021 pandemic peak. M&A activity followed. Companies that survived the rate drought suddenly found liquidity at reasonable valuations.

This is the meta-pattern every biotech investor needs to understand: the sector doesn’t move on one drug at a time. It moves in rate-driven cycles that amplify or crush every stock simultaneously.

The 3-Variable Mental Model

When evaluating any biotech position, weigh these three variables together:

1. Rate Direction. What is the 10-year Treasury yield doing? Check it at Treasury.gov or any financial data terminal. Rising rates compress all future cash flows. Falling rates expand them. If rates are rising, every biotech you own is working against a headwind.

2. Catalyst Calendar. How far away is the value driver? A drug with a PDUFA date in 3 months is less rate-sensitive than a platform biotech whose first Phase 3 data reads out in 2028. The closer the catalyst, the less time discounting can erode it. For more on finding and trading those catalysts, see the guide to FDA catalyst trading.

3. Cash Runway. How long until the company needs more money? Under 12 months is a red flag regardless of rates. Over 24 months gives you a buffer. When rates are rising, demand runway above 18 months because the next raise will be expensive. For a framework on sizing positions that can survive binary events, see the portfolio construction guide.

Common Mistakes

• Ignoring rates entirely. The most common mistake. A biotech investor who only looks at pipeline and ignores the 10-year Treasury is flying blind. In 2022, the broadest biotech ETF fell 64%. No amount of stock-picking skill could outrun that.

• Buying long-duration biotech during a rate-hiking cycle. Platform companies, gene therapy names with distant revenue, and early-stage companies get hit hardest. If rates are rising, the same pipeline thesis should lead you to names with nearer-term catalysts or companies that already have revenue.

• Treating rate cuts as a guaranteed tailwind. Rate cuts help biotech, but they only work if the reason for the cut isn’t a recession. If the Fed is cutting because the economy is contracting, credit spreads widen and risk appetite disappears. Biotech underperforms in recessions regardless of rates.

• Betting on a single catalyst without factoring the macro backdrop. A great PDUFA catalyst in a rising-rate environment can deliver a 15% pop instead of a 40% pop because the sector bid is missing. The same approval in a falling-rate environment can be a rocket.

Final Checklist

Before buying any biotech stock, answer these four questions:

• What is the 10-year Treasury yield today, and what direction is it moving?
• How many years until this company’s value driver (approval, revenue inflection) materializes?
• Does the company have more than 18 months of cash runway at current burn rates?
• In the current rate environment, should you be adding duration (far-off catalysts) or reducing it (near-term catalysts)?

The Fed doesn’t care about your clinical trial data. But its decisions will determine whether your biotech portfolio is up 30% or down 40% this year. Check the 10-year yield before you check the pipeline.